Natural History of Pediatric Ulcerative Colitis

  • Jeffrey S. Hyams


Inflammatory Bowel Disease Ulcerative Colitis Severe Colitis Major Histocompatability Complex Mayo Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Goel KM, Shanks RA. Long-term prognosis of children with ulcerative colitis. Arch Dis Child 1973;48:337–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Michener WM, Farmer RG, Mortimer EA. Long-term prognosis of ulcerative colitis with onset in childhood or adolescence. J Clin Gastroenterol 1979;1:301–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr 1996;129:81–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Langholz E, Munkholm P, Krasilnikoff PA, Binder V. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997;32:139–47.PubMedCrossRefGoogle Scholar
  5. 5.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;1041–8.Google Scholar
  6. 6.
    Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3–11.PubMedGoogle Scholar
  7. 7.
    Hyams J, Davis P, Lerer T, et al. Clinical outcome of ulcerative proctitis in children. J Pediatr Gastroenterol Nutr 1997;25:149–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002;CD000544.Google Scholar
  9. 9.
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:204–11.PubMedGoogle Scholar
  10. 10.
    Faubion WA, Jr., Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006;4:1118–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279–88.PubMedCrossRefGoogle Scholar
  13. 13.
    Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003;178:339–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 2006;55:437–41.PubMedCrossRefGoogle Scholar
  15. 15.
    Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004;99:1122–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999;28:54–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990;117:809–14.PubMedCrossRefGoogle Scholar
  19. 19.
    D’Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995;38:474–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498–9.PubMedGoogle Scholar
  23. 23.
    Arts J, D’Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998;12:973–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;7 Suppl 1:S30–3.PubMedCrossRefGoogle Scholar
  26. 26.
    Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577–84.PubMedCrossRefGoogle Scholar
  27. 27.
    Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998–1002.PubMedCrossRefGoogle Scholar
  28. 28.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.PubMedCrossRefGoogle Scholar
  29. 29.
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–11.PubMedCrossRefGoogle Scholar
  30. 30.
    Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004;39:166–70.PubMedCrossRefGoogle Scholar
  31. 31.
    Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004;38:298–301.PubMedCrossRefGoogle Scholar
  32. 32.
    Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN, Jr., Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005;11:213–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499–507.PubMedCrossRefGoogle Scholar
  35. 35.
    Sandborn WJ, Baumgart DC, Targan SR, et al. Long-term outcome following visilizumab for the treatment of intravenous steroid-refractory ulcerative colitis (IVSRUC). Gastroenterology 2007;132:A506.Google Scholar
  36. 36.
    Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology 1977;73:828–32.PubMedGoogle Scholar
  37. 37.
    Carbonnel F, Lavergne A, Lemann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39:1550–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004;19:1247–52.PubMedCrossRefGoogle Scholar
  39. 39.
    Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004;19:1079–87.PubMedCrossRefGoogle Scholar
  41. 41.
    Bouma G, Crusius JB, Garcia-Gonzalez MA, et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999;115:294–300.PubMedCrossRefGoogle Scholar
  42. 42.
    Trachtenberg EA, Yang H, Hayes E, et al. HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations. Hum Immunol 2000;61:326–33.PubMedCrossRefGoogle Scholar
  43. 43.
    Ahmad T, Armuzzi A, Neville M, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 2003;62:527–35.PubMedCrossRefGoogle Scholar
  44. 44.
    de la Concha EG, Fernandez-Arquero M, Lopez-Nava G, et al. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenterology 2000;119:1491–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Bagnoli S, Putignano AL, Melean G, et al. Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene. Inflamm Bowel Dis 2004;10:705–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Kugathasan S, Dubinsky M, Keljo D, et al. Severe colitis in children. J Pediatr Gastroenterol Nutr 2005;41:375–85.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jeffrey S. Hyams
    • 1
  1. 1.Head, Division of Digestive Diseases and Nutrition, Connecticut Children’s Medical CenterUniversity of Connecticut School of MedicineHartfordUSA

Personalised recommendations